ERBB2 and cancer: These ADCs were tested against different HER2-positive (MCF-7, BT-474, and SKBR-3) and HER2-negative (MDA-MB-231, and MCF-10A) cell lines, and demonstrated the targeting efficacy of site-specific gold-containing ADCs against HER2-positive cancer cells.